Bristol Myers Squibb will cut $2 billion in costs by the end of 2027, a move aimed at long-term growth as the company prepares for patent expirations on key treatments, CNBC reported Feb. 6.

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal ...

This was the stock's third consecutive day of losses.

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...

Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.

PHILADELPHIA – Josh Myers couldn’t have picked a worse way to venture into his uncertain future, even if the Green Bay Packers center felt he “got lucky” Sunday. “I thought I broke my leg,” Myers said ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...